We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
The current EXEL market cap is 9.7B. The company's latest EPS is USD 0.7275 and P/E is 46.72.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 471.92M | 479.65M | 425.23M | 637.18M | 539.54M |
| Operating Income | -17.58M | 81.79M | 29.46M | 275.87M | 187.75M |
| Net Income | 1.04M | 85.52M | 37.32M | 226.12M | 117.97M |
| Year End 29 December 2023 | 2020 | 2021 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 967.78M | 987.54M | 1.43B | 1.61B | 1.83B |
| Operating Income | 369.47M | 110.06M | 286.67M | 201.48M | 170.89M |
| Net Income | 321.01M | 111.78M | 231.06M | 182.28M | 207.77M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 2.98B | 2.94B | 2.8B | 2.77B | 2.96B |
| Total Liabilities | 629.29M | 678.45M | 675.74M | 653.39M | 684.86M |
| Total Equity | 2.35B | 2.26B | 2.13B | 2.12B | 2.28B |
| Year End 29 December 2023 | 2020 | 2021 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 1.89B | 2.14B | 2.62B | 3.07B | 2.94B |
| Total Liabilities | 199.7M | 258.22M | 405.62M | 583.06M | 678.45M |
| Total Equity | 1.69B | 1.88B | 2.21B | 2.49B | 2.26B |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 322.75M | 333.32M | 68.82M | 188.37M | 459.71M |
| Investing | -88.69M | -26.96M | 111.79M | 193.57M | -23.58M |
| Financing | -339.88M | -546.05M | -184.05M | -446.47M | -440.77M |
| Year End 29 December 2023 | 2020 | 2021 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 526.96M | 208.98M | 400.8M | 362.61M | 333.32M |
| Investing | -587.25M | -131.22M | -42.88M | -524.41M | -26.96M |
| Financing | 12.55M | -25.13M | -14.8M | 586k | -546.05M |
| Market Cap | 9.7B |
| Price to Earnings Ratio | 46.72 |
| Price to Sales Ratio | 5.3 |
| Price to Cash Ratio | 36.91 |
| Price to Book Ratio | 4.29 |
| Dividend Yield | - |
| Shares Outstanding | 285.58M |
| Average Volume (1 week) | 1.45M |
| Average Volume (1 Month) | 2.01M |
| 52 Week Change | 42.43% |
| 52 Week High | 36.97 |
| 52 Week Low | 19.20 |
| Spread (Intraday) | 0.58 (1.69%) |
| Company Name | Exelixis Inc |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.exelixis.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
